GO is FDA approved for the treatment of newly diagnosed CD33 positive AML in children ≥2 years of age and thus is often utilized with many different standard chemotherapy regimens in pediatric patients with CD33 positive AML. This evidence concerns the gene CD33 and acute myeloid leukemia.